nils-herrmann/clean_scirepeval huggingface dataset:
Myeloperoxidase is increased in human cerebral aneurysms and increases formation and rupture of cerebral aneurysms in mice.

Cerebral aneurysm (CA) affects 3% of the population and is associated with hemodynamic stress and inflammation. Myeloperoxidase, a major oxidative enzyme associated with inflammation, is increased in patients with CA, but whether myeloperoxidase contributes to CA is not known. We tested the hypotheses that myeloperoxidase is increased within human CA and is critical for formation and rupture of CA in mice.



Blood was drawn from the lumen of CAs and femoral arteries of 25 patients who underwent endovascular coiling of CA, and plasma myeloperoxidase concentrations were measured with ELISA. Effects of endogenous myeloperoxidase on CA formation and rupture were studied in myeloperoxidase knockout mice and wild-type (WT) mice using an angiotensin II-elastase induction model of CA. In addition, effects of myeloperoxidase on inflammatory gene expression in endothelial cells were analyzed.



Plasma concentrations of myeloperoxidase were 2.7-fold higher within CA than in femoral arterial blood in patients with CA. myeloperoxidase-positive cells were increased in aneurysm tissue compared with superficial temporal artery of patients with CA. Incidence of aneurysms and subarachnoid hemorrhage was significantly lower in myeloperoxidase knockout than in WT mice. In cerebral arteries, proinflammatory molecules, including tumor necrosis factor-α, cyclooxygenase-2 (COX2), chemokine (C-X-C motif) ligand 1 (CXCL1), chemokine (C motif) ligand (XCL1), matrix metalloproteinase (MMP) 8, cluster of differentiation 68 (CD68), and matrix metalloproteinase 13, and leukocytes were increased, and α-smooth muscle actin was decreased, in WT but not in myeloperoxidase knockout mice after induction of CA. Myeloperoxidase per se increased expression of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 in endothelial cells.



These findings suggest that myeloperoxidase may contribute importantly to formation and rupture of CA.
Effects of vitamin D supplementation on markers of vascular function after myocardial infarction--a randomised controlled trial.

Low vitamin D levels are common, and are associated with a higher incidence of future vascular events. We tested whether vitamin D supplementation could improve endothelial function and other markers of vascular function in patients with a history of myocardial infarction.



Parallel group, placebo-controlled, double-blind randomised trial. Patients with a history of myocardial infarction were randomised to receive 100,000 units of oral vitamin D3 or placebo at baseline, 2 months and 4 months. Outcomes were measured at baseline, 2 and 6 months. Reactive hyperaemia index on fingertip plethysmography was the primary outcome. Secondary outcome measures included blood pressure, cholesterol, C-reactive protein, von Willebrand factor, tumour necrosis factor alpha, E-selectin, B-type natriuretic peptide, thrombomodulin and 25-hydroxyvitamin D levels.



75 patients were randomised, mean age 66 years. 74/75 (99%) completed 6 month follow-up. 25 hydroxyvitamin D levels increased in the intervention group relative to placebo (+13 vs +1 nmol/L, p=0.04). There was no between-group difference in change in reactive hyperaemia index between baseline and 6 months (-0.18 vs -0.07, p=0.40). Of the secondary outcomes, only C-reactive protein showed a significant decline in the intervention arm relative to placebo at 6 months (-1.3 vs 2.0mg/L, p=0.03). Systolic blood pressure (+1.4 vs +2.3 mmHg, p=0.79), diastolic blood pressure (+2.0 vs +0.8 mmHg, p=0.54) and total cholesterol (+0.26 vs +0.24 mmol/L, p=0.88) showed no between-group difference at 6 months.



Supplementation with vitamin D did not improve markers of vascular function in patients with a history of myocardial infarction.
Factors important to patients' quality of life at the end of life.

When curative treatments are no longer options for patients dying of cancer, the focus of care often turns from prolonging life to promoting quality of life (QOL). Few data exist on what predicts better QOL at the end of life (EOL) for advanced cancer patients. The purpose of this study was to determine the factors that most influence QOL at the EOL, thereby identifying promising targets for interventions to promote QOL at the EOL.



Coping With Cancer is a US multisite, prospective, longitudinal cohort study of 396 advanced cancer patients and their informal caregivers who were enrolled from September 1, 2002, through February 28, 2008. Patients were followed up from enrollment to death a median of 4.1 months later. Patient QOL in the last week of life was a primary outcome of Coping With Cancer and the present report.



The following set of 9 factors, preceded by a sign indicating the direction of the effect and presented in rank order of importance, explained the most variance in patients' QOL at the EOL: 1 = (-) intensive care unit stays in the final week (explained 4.4% of the variance in QOL at the EOL), 2 = (-) hospital deaths (2.7%), 3 = (-) patient worry at baseline (2.7%), 4 = (+) religious prayer or meditation at baseline (2.5%), 5 = site of cancer care (1.8%), 6 = (-) feeding-tube use in the final week (1.1%), 7 = (+) pastoral care within the hospital or clinic (1.0%), 8 = (-) chemotherapy in the final week (0.8%), and 9 = (+) patient-physician therapeutic alliance at baseline (0.7%). The vast majority of the variance in QOL at the EOL, however, remained unexplained.



Advanced cancer patients who avoid hospitalizations and the intensive care unit, who are less worried, who pray or meditate, who are visited by a pastor in the hospital/clinic, and who feel a therapeutic alliance with their physicians have the highest QOL at the EOL.
Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenia outpatients: Clinical and social outcome at 2 years

To evaluate a novel approach to the prophylaxis of schizophrenic relapse characterised by administration of brief courses of neuroleptic for the earliest non-psychotic signs of relapse (prodromal symptoms).



Two year follow up of subjects randomised, double blind, to receive either active (control group) or placebo (intermittent group) depot neuroleptic medication. Both groups received brief courses of oral neuroleptic when prodromal symptoms or relapse occurred.



Psychiatric outpatient department, Charing Cross Hospital, London.



54 Stable patients in remission who met the American Psychiatric Association's DSM-III criteria for schizophrenia on the basis of case notes.



Survival without relapse, survival without hospitalisation, point prevalence of extrapyramidal side effects and tardive dyskinesia, structured assessment of social functioning (social adjustment scale II), and frequency of prodromal symptoms.



Of 19 relapses recorded over two years, 10 (53%) were preceded by non-psychotic prodromal signs. Survival rates for both relapse and hospitalisation were worse with intermittent treatment than continuous treatment over the two year follow up: 92% of controls and only 54% of patients given intermittent treatment survived the two year period without hospitalisation. Prolonged or frequent relapses as well as episodes of prodromal symptoms were more frequent with intermittent treatment. Lower scores for extrapyramidal side effects were recorded in the intermittent treatment group, but periodic assessments of social functioning failed to show any social advantages from this.



The findings are at variance with a previous report of one year follow up in this cohort and attest to the superiority of continuous depot neuroleptic prophylaxis in preventing both psychotic and neurotic or dysphoric morbidity in schizophrenia.
Methods and management of the healthy brain study: a large multisite qualitative research project.

To describe processes used in the Healthy Brain project to manage data collection, coding, and data distribution in a large qualitative project, conducted by researchers at 9 universities in 9 states.



Project management protocols included: (a) managing audiotapes and surveys to ensure data confidentiality, data tracking and distribution; (b) managing qualitative data to ensure the accuracy and confidentiality of transcription; (c) training in qualitative methods and use of qualitative software; and (d) managing participant survey data and analysis.



The project team coded and managed qualitative and survey data for 69 focus groups with more than 500 participants. Multiple interactive training sessions in qualitative data analysis and use of qualitative software (ATLAS.ti) were conducted. To develop a codebook, 2 teams used an open-coding process to identify codes and develop definitions; 2 team members integrated and conceptually organized these results into an initial codebook. For the audio-recordings from each research site, 2 or 3 team members hand coded 1 transcript and calculated interrater agreement (.80 or higher).



Using clear protocols, participatory training sessions, team-based coding, and frequent communication among team members via e-mail and regular in-person meetings promotes effective management of large-scale qualitative research projects.
Impaired Control Scale: cross-validation and relationships with treatment outcome.

(1) To cross-validate Australian findings on the Impaired Control Scale (ICS) in an English sample of problem drinkers. (2) To examine a possible improvement to the scoring of the ICS. (3) To explore the relationship of the ICS to treatment outcome.



In a repeated measures design, questionnaires and interviews were administered by trained staff during treatment and again at 6 months follow-up.



Two alcohol and drug treatment services in Newcastle and Liverpool (UK).



Two hundred and twenty-nine problem drinkers attending as in- or outpatients, with abstinence or moderation treatment goals.



ICS scores; typical weekly alcohol consumption (units); degree of alcohol-related problems; severity of alcohol dependence; and classification of outcome using consumption levels and current alcohol-related problems, with collateral confirmation of self-reports.



The satisfactory reliability and validity of the ICS was confirmed in an English sample of problem drinkers in treatment. An improved "substitution method" of scoring was developed to give a single measure of impaired control for all subjects irrespective of degree of attempted control. ICS scores were significantly correlated with treatment outcome and, among a subgroup of subjects who had aimed at abstinence but failed, predicted outcome status after the effects of degree of dependence had been extracted.



Impaired control over alcohol consumption can be measured in a reliable and valid fashion by the ICS. The ICS has potential uses in research on impaired control and as a clinical assessment tool.
Effect of glyburide-metformin combination tablet in patients with type 2 diabetes.

To evaluate the efficacy and safety of glyburide/metformin combined tablet compared to glyburide or metformin alone in patients with type 2 diabetes.



In this 16-week, multicenter, randomized, double-blind, 4-arm and parallel clinical trial study, 100 patients with type 2 diabetes mellitus were recruited and 76 patients were available for statistical analysis at the end of the study. After 1 week of placebo washout period, eligible patients were randomly assigned into 1 of 4 treatment groups: glyburide 5 mg b.i.d.; metformin 500 mg b.i.d.; glyburide/metformin 2.5 mg/500 mg b.i.d.; or glyburide/metformin 5.0 mg/500 mg b.i.d. The doses were titrated every 2 weeks to a maximum of 4 tablets per day if the patients fasting plasma glucose (FPG) still exceeded 140 mg/dL. Efficacy was evaluated by the changes from baseline in glycosylated hemoglobin (HbA1c) and FPG at week 16. Adverse events were recorded and summarized by treatment group.



At week 16, patients who received glyburide/metformin 2.5 mg/500 mg or 5.0 mg/500 mg tablets had greater reductions in FPG (all p<0.001) compared with glyburide or metformin monotherapy. Patients who took glyburide/ metformin 2.5 mg/500 mg tablet and glyburide/metformin 5.0 mg/500 mg tablet had significant decreases in HbA1c (both p<0.0125). Furthermore, treatment with glyburide/metformin 2.5 mg/500 mg resulted in significantly greater reduction in HbA1c compared to glyburide or metformin (-1.77%, p<0.001 and -1.34%, p=0.002), and treatment with glyburide/metformin 5.0 mg/500 mg resulted in significant lowering of HbA1c compared to glyburide or metformin alone (-1.73%, p<0.001 and -1.30%, p=0.005). Both the glyburide/metformin 2.5 mg/500 mg and glyburide/metformin 5.0 mg/500 mg combination therapy groups experienced fewer gastrointestinal adverse events than the metformin monotherapy group.



Both glyburide/metformin 2.5 mg/500 mg and glyburide/metformin 5.0 mg/500 mg combination therapy were efficacious and well tolerated in the treatment of Chinese patients with type 2 diabetes mellitus.
Indexing million of packets per second using GPUs

Network traffic recorders are devices that record massive volumes of network traffic for security applications, like retrospective forensic investigations. When deployed over very high-speed networks, traffic recorders must process and store millions of packets per second. To enable interactive explorations of such large traffic archives, packet indexing mechanisms are required. Indexing packets at wire rates (10 Gbps and above) on commodity hardware imposes unparalleled requirements for high throughput index creation. Such indexing throughputs are presently untenable with modern indexing technologies and current processor architectures. In this work, we propose to intelligently offload indexing to commodity General Processing Units (GPUs). We introduce algorithms for building compressed bitmap indexes in real time on GPUs and show that we can achieve indexing throughputs of up to 185 millions records per second, which is an improvement by one order of magnitude compared to the state-of-the-art. This shows that indexing network traffic at multi-10-Gbps rates is well within reach.
Early angiographic results of multivessel off-pump coronary artery bypass grafting.

Recently off-pump coronary artery bypass grafting (CABG) is being widely used for coronary revascularization. However, there is some evidence that off-pump surgery increases the risk of recurrent angina and the need for reintervention, suggesting poor graft quality or incomplete revascularization. We describe our experience to demonstrate the feasibility of multiple coronary revascularization in off-pump CABG (OPCAB).



From January 2002 to March 2003, 168 patients underwent OPCAB at our institute. In 16 of them, 6 to 9 vessels were revascularized in each patient. There were 14 males and 2 females with a mean age of 66 years (47 to 74 years). All patients had triple-vessel disease. Ten patients received in situ arterial grafts only which were harvested with the skeletonization technique using an ultrasonic scalpel. We used the Starfish heart positioner to expose lateral, posterior, and inferior walls of the heart with minimal hemodynamic compromise.



All patients were discharged from the hospital without any serious complications. Postoperative angiography was performed in 87.5% within 1 month after operation. The patency rate was 96.6%.



These results indicate that complete revascularization can be achieved in OPCAB in patients with diffuse coronary arterial disease. Complete revascularization with in situ arterial conduits only is technically feasible and yields a high early graft patency, even in the off-pump situation.
Erratum to: Eating two larger meals a day (breakfast and lunch) is more effective than six smaller meals in a reduced-energy regimen for patients with type 2 diabetes: a randomised crossover study

Unfortunately the values forΔ HFC in the Abstract and main text and the values on the y-axis of the graph  2b were presented as fractions rather than percentages and were therefore 100 times lower than they should have been. The correct values for Δ HFC were −3.0% (95% CI −3.3%, −2.7%) for A6 vs −4.0% (95% CI −4.1%, −3.5%) for B2 (p=0.009). A corrected version of the graph is shown here.
Cardiovascular events and intensity of treatment in polycythemia vera.

Current treatment recommendations for patients with polycythemia vera call for maintaining a hematocrit of less than 45%, but this therapeutic strategy has not been tested in a randomized clinical trial.



We randomly assigned 365 adults with JAK2-positive polycythemia vera who were being treated with phlebotomy, hydroxyurea, or both to receive either more intensive treatment (target hematocrit, <45%) (low-hematocrit group) or less intensive treatment (target hematocrit, 45 to 50%) (high-hematocrit group). The primary composite end point was the time until death from cardiovascular causes or major thrombotic events. The secondary end points were cardiovascular events, cardiovascular hospitalizations, incidence of cancer, progression to myelofibrosis, myelodysplasia or leukemic transformation, and hemorrhage. An intention-to-treat analysis was performed.



After a median follow-up of 31 months, the primary end point was recorded in 5 of 182 patients in the low-hematocrit group (2.7%) and 18 of 183 patients in the high-hematocrit group (9.8%) (hazard ratio in the high-hematocrit group, 3.91; 95% confidence interval [CI], 1.45 to 10.53; P=0.007). The primary end point plus superficial-vein thrombosis occurred in 4.4% of patients in the low-hematocrit group, as compared with 10.9% in the high-hematocrit group (hazard ratio, 2.69; 95% CI, 1.19 to 6.12; P=0.02). Progression to myelofibrosis, myelodysplasia or leukemic transformation, and bleeding were observed in 6, 2, and 2 patients, respectively, in the low-hematocrit group, as compared with 2, 1, and 5 patients, respectively, in the high-hematocrit group. There was no significant between-group difference in the rate of adverse events.



In patients with polycythemia vera, those with a hematocrit target of less than 45% had a significantly lower rate of cardiovascular death and major thrombosis than did those with a hematocrit target of 45 to 50%. (Funded by the Italian Medicines Agency and others; ClinicalTrials.gov number, NCT01645124, and EudraCT number, 2007-006694-91.).
Brain MR post-gadolinium contrast in multiple sclerosis: the role of magnetization transfer and image subtraction in detecting more enhancing lesions

Our purpose was to evaluate the role of magnetization transfer and image subtraction in detecting more enhancing lesions in brain MR imaging of patients with multiple sclerosis (MS). Thirty-one MS patients underwent MR imaging of the brain with T1-weighted spin echo sequences without and with magnetization transfer (MT) using a 1.5 T imager. Both sequences were acquired before and after intravenous injection of a paramagnetic contrast agent. Subtraction images in T1-weighted sequences were obtained by subtracting the pre-contrast images from the post-contrast ones. A significant difference was found between the numbers of enhanced areas in post-gadolinium T1-weighted images without and with MT (p=0.020). The post-gadolinium T1-weighted images with MT allowed the detection of an increased (13) number of enhancing lesions compared with post-gadolinium T1-weighted images without MT. A significant difference was also found between the numbers of enhanced areas in post-gadolinium T1-weighted images without MT and subtraction images without MT (p=0.020). The subtraction images without MT allowed the detection of an increased (10) number of enhancing lesions compared with post-gadolinium T1-weighted images without MT. Magnetization transfer contrast and subtraction techniques appear to be the simplest and least time-consuming applications to improve the conspicuity and detection of contrast-enhancing lesions in patients with MS.
The RegEx trial: a randomized, double-blind, placebo- and active-controlled pilot study combining regadenoson, a selective A(2A) adenosine agonist, with low-level exercise, in patients undergoing myocardial perfusion imaging.

Although vasodilator stress myocardial perfusion imaging (MPI) is increasingly performed with exercise, adenosine A(2A) receptor agonists have not been studied with exercise.



To determine the safety of administering regadenoson during exercise and, secondarily, to evaluate image quality, patient acceptance, and detection of perfusion defects.



Patients requiring pharmacologic MPI received a standard adenosine-supine protocol (AdenoSup, n = 60) and were then randomized (2:1) in a double-blind manner to low-level exercise with bolus intravenous injection of regadenoson (RegEx, n = 39) or placebo (PlcEx, n = 21).



Adverse events occurred in 95%, 77%, and 33% of patients receiving AdenoSup, RegEx, and PlcEx, respectively. Peak heart rate was 13 beats per minute (bpm) and 21 bpm greater following RegEx compared to that following PlcEx and AdenoSup, respectively (P = .006 and <.001). Change from baseline in mean systolic blood pressure (SBP), change from baseline to nadir SBP, and percentage of patients with a decline in SBP by > or = 20 mm Hg showed no important differences between RegEx and PlcEx. No occurrences of 2nd degree or higher AV block were observed following RegEx or PlcEx; one patient developed 2nd degree AV block following AdenoSup. The mean heart-to-liver and heart-to-gut ratios were improved on RegEx vs AdenoSup: 0.85 (0.34) vs 0.65 (0.26), P < .001 and 1.1 (0.36) vs 0.97 (0.34), P < .001, respectively. Compared to AdenoSup, 70% of patients felt RegEx was much or somewhat better.



Combining regadenoson with low-level exercise is feasible, well tolerated, and associated with fewer side effects compared to AdenoSup.